A simple but revolutionary test to improve early detection for dementia and Alzheimer’s disease could soon be helping patients and their families, thanks to a significant £1.5 million funding boost awarded to the universities of Bath and Bristol.
Article continues below
br>
Supported by the National Institute for Health and Care Research (NIHR)’s Invention for Innovation (i4i) funding, the project will see researchers Drs George Stothart and Liz Coulthard scale-up testing and development for their innovative ‘Fastball EEG’ dementia assessment at Southmead Hospital, Bristol.
‘Fastball’ is a passive, completely non-invasive test which measures patients’ brain waves whilst they watch a series of flashing images displayed on a screen. Developed in-house by the researchers, the technology requires users to wear an electroencephalogram (EEG) headset, which is linked to a computer for analysis.
Previous research from Dr Stothart, Dr Coulthard and colleagues has shown Fastball to be highly effective at picking up small, subtle changes in brain waves which occur when a person remembers an image.
They have demonstrated that this response changes as a person develops dementia, offering hope as a breakthrough for early diagnosis.
Dementia is typically diagnosed too late, at a point at which the disease has damaged the brain beyond repair. This can be up to 20 years after dementia first started to develop.
Current diagnosis often relies on a series of subjective questions to test a person’s memory, which is limited and can be impacted by a person’s education, language skills or nervousness.
Fastball, by contrast, is completely passive. This means the person doing the test does not need to understand the task or be aware of their memory response.
Crucially, it is also portable, meaning that diagnoses in the future could be carried out anywhere, including in a patient’s home.
By testing more people earlier and more regularly, the team believes it could help lower the age of diagnosis by up to five years in the short-term and by more in the future.
Recent findings from Alzheimer’s Research UK suggested that many people would want to know if they will develop Alzheimer’s in the future, even if they don’t yet have symptoms.
Through the new five-year NIHR project, the team will test Fastball on more than 1000 patients in a working dementia clinic at Southmead Hospital in Bristol. This represents the biggest study of any kind to use EEG to screen for Alzheimer’s disease with a goal to enrol a diverse patient population.
They will also work with Belfast-based commercial partners Cumulus Neuroscience Ltd to develop the technology into a product that can be rolled out wider across the NHS and beyond.
It will use the existing Cumulus dry electrode 16-lead EEG headset that is UKCA marked and has FDA 510-K clearance.
Dr George Stothart, project co-lead and a cognitive neuroscientist based in the Department of Psychology at the University of Bath, said: “Quicker, more accurate ways to diagnose dementia are greatly needed so that patients can get treatments earlier and families can plan better for the future, which is why we are so excited for the potential of Fastball EEG and the development of our work through this significant new funding and the collaborations it will enable.â€
Cumulus Neuroscience combines patented technology and in-house expertise to capture large amounts of real-world, clinical data repeated over time, across multiple behavioural and physiological domains in the clinic or a patient’s home.
It leverages a UKCA marked dry sensor 16-lead EEG headset synced to a novel, tablet-based neuro-assessment platform.
Through the new NIHR funding, Fastball EEG is one of six projects announced as part of a major £11 million investment to develop enhanced digital approaches for early detection and diagnosis for dementia. ■